In #CALR-mutated #ET, high allele burden ≥ 35% was associated with a lower likelihood of achieving complete hematological response and with an increased risk of arterial thrombosis, progression to #myelofibrosis and death
#MPN#GEMFIN@Hemasphere_EHA
https://t.co/gzmIGUNcU9
📢 ¡Ya disponible la edición 2025 del Manual de Recomendaciones GEMFIN en Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas!
Una herramienta clave para la práctica clínica.
📘 Descárgalo aquí 👉 https://t.co/GlS9nW53nd
#GEMFIN#MPN#Hematología@sehh_es@HematoRYC
🔴 Comienza nuestra IX Reunión Anual del grupo GEMFIN. Excelente programa educacional y revisión de proyectos en marcha. ¡Más de 160 asistentes! Un éxito de participación. @sehh_es#GEMFIN#Hematología#MPN
Outstanding talk by Dr. William Vainchenker at the GEMFIN Annual Meeting:
“Twenty years since the discovery of JAK2 V617F. Molecular advances in MPNs since then.”
A privilege to learn from one of the pioneers in the field. #MPNs#JAK2#Hematology#GEMFIN2025
¡Recién salidas del horno! 📘 Presentamos en nuestra reunión anual las nuevas guías GEMFIN.
Esperamos que sean una herramienta de gran utilidad para todos los compañeros implicados en el manejo de las NMP. #GEMFIN2025#NMP#Hematología@sehh_es
It's out!! I am thrill to share with you our new paper in @BloodJournal where we show that JAK2 46/1 haplotype regulates PD-L1 expression. This opens the door to new research lines and, who knows, future treatments for our MPN patients.
https://t.co/XT5GnfQKnx
Our latest study from the GEMFIN group has just been published in Blood Cancer Journal!
We report real-world data on the efficacy and safety of momelotinib in patients with myelofibrosis: https://t.co/gW1vVmgFBb
@sehh_es
📢Nos complace compartir que nuestros compañeros, @GonzaloHEM y JC Hernández-Boluda, han publicado dos artículos originales en la prestigiosa revista Blood.Gran logro de la Hematología española y GEMFIN. Enhorabuena a los autores! 👏 @sehh_es@mpnspain_
Very happy to be part of this international collaboration 🇨🇦🇫🇷🇪🇸🇳🇿🇩🇪 defining the VITT-like Monoclonal Gammopathy of Thrombotic Significance @hospitalclinic https://t.co/vlrJ3HX9jx
High-risk patients achieving complete hematological response to first-line hydroxyurea showed a reduced risk of arterial thrombosis, a lower rate of progression to myelofibrosis and better survival: Data from Spanish Registry of ET
#MPN@LeukemiaJnl
https://t.co/KESJi8tCii
High-risk patients achieving complete hematological response to first-line hydroxyurea showed a reduced risk of arterial thrombosis, a lower rate of progression to myelofibrosis and better survival: Data from Spanish Registry of ET
#MPN@LeukemiaJnl
https://t.co/KESJi8tCii